Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.
In Hong Kong, Bairong (1569395D CH) closed a day earlier and was priced at the top end, raising HK$3.94bn (US$508m). Bilibili Inc (9626 HK) raised US$2.6bn at HK$808 per share. Bilibili will list on Monday while Bairong on Wednesday.
Tencent-backed Linklogis (LINK HK) launched its IPO on Friday and boasts an impressive cornerstone line-up. The deal will price this coming Wednesday:
We also looked at two upcoming Hong Kong biotech IPOs, namely Shanghai Bio-Heart Biological Technology (BHT HK) and Kindstar Globalgene Technology (1868874D HK) :
In the US, China ADRs have been hammered in the past week due to the Holding Foreign Companies Accountable Act by the SEC. Sumeet addressed the market’s knee jerk reaction and how the sentiment might have been exaggerated in the note:
China ADRs - SEC Notice - Instead of Three, Probably Have Four Years till 2025 - Correction Overdone
Affected by poor sentiment, Zhihu Technology (ZH US) priced its IPO at the bottom end. Peers took another leg down on Friday on the back of rumors of education policies likely to be changed. Zhihu’s share price opened 15.3% below IPO price and went on to trade lower intraday. We published an update regarding a rumoured document. We thought the selldown for Zhihu was overdone.
We also shared our thoughts on competitive landscape and valuation of Smart Share Global (EM US) :
The previous week, we initiated coverage on Monde Nissin Corp (0191881D PM), which is expected to raise US$1bn in its upcoming IPO in the Philippines. This week, we focused on the negatives of the company which can be found:
Kalyan Jewellers traded down 15% on its debut despite having a decently strong line-up of investors backing the deal, which included GIC. As per Sumeet’s earlier notes, this seemed to be a case of mispricing as we see no reason to pay an expensive valuation for company with no track record of any growth.:
On placements the past week, we covered Japan’s freee (4478 JP) placement, that was priced at the bottom end on 25th Mar 21:
Our overall accuracy rate is 73.9% for IPOs and 67.2% for Placements
(Performance measurement criteria is explained at the end of the note)
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.